GMED — Globus Medical, Inc.

Summary of Globus Medical (GMED) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025:
  • Revenue: $2.939 billion (up 16.7% YoY)
  • Non-GAAP EPS: $3.98 (up 30.8% YoY)
  • Adjusted EBITDA Margin: 33.4%
• Q4 2025:
  • Revenue: $826.4 million (up 25.7% YoY)
  • Non-GAAP EPS: $1.28 (up 52.1% YoY)
  • Base business revenue: $726.7 million (up 10.6% YoY)
  • Adjusted Gross Margin: 69.2% (up from 67.1% YoY)

2. Strategic Updates and Business Highlights

• Continued momentum in U.S. Spine business with 10% growth in Q4, marking 48 weeks of consecutive growth.
• Successful integration of Nevro, contributing $99.7 million in revenue for Q4 and achieving adjusted EBITDA margin of 21.2%.
• Launched six new spine products in Q4, enhancing the product portfolio.
• Enabling Technologies revenue reached $55.6 million, growing 18.5% YoY, driven by increased sales of EGPS systems.
• Focus on operational efficiency and inventory management led to improved gross margins.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Revenue expected between $3.18 billion and $3.22 billion (growth of 8.2% to 9.6% YoY).
  • Non-GAAP EPS guidance increased to $4.40 to $4.50 (growth of 10.6% to 13.1% YoY).
  • Anticipated adjusted gross margin improvement to 69% to 70%.

4. Bad News, Challenges, or Points of Concern

• International Growth: The international business faced challenges, particularly in the APAC region, with expectations for gradual recovery in 2026.
• Market Share and Competition: Concerns about competitive pressures, especially with new robotic systems from competitors, though management remains confident in their unique offerings.
• Lumpiness in Nevro's Performance: The integration of Nevro may lead to inconsistent growth patterns in the short term.
• R&D Investment: While R&D expenses decreased as a percentage of sales, there is a need for increased investment to drive future innovation.

5. Notable Q&A Insights

• Management acknowledged the sustainability of U.S. Spine growth but noted potential for a slowdown in legacy musculoskeletal growth in 2026 due to various factors, including changes in deal structures and market dynamics.
• The company is adopting more flexible leasing options to drive capital placements, which may result in revenue recognition delays.
• There is cautious optimism regarding the Enabling Technologies segment, with expectations for improved deal closure timelines in 2026.
• Management emphasized the importance of maintaining focus on internal objectives and leveraging their competitive advantages in the evolving market landscape.

Overall, Globus Medical reported a strong finish to 2025, with significant growth driven by its U.S. Spine and Enabling Technologies segments, while also navigating challenges related to international markets and competitive pressures. The outlook for 2026 remains positive, with strategic initiatives aimed at sustaining growth and enhancing profitability.